// App-Quantinova.ai

L15 : Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: A Randomized Phase IIIb Study

Researchers

Presenter

  • Xenofon Baraliakos

Principal Investigators

  • Mikkel Østergaard

  • Denis Poddubnyy

  • Désirée van der Heijde

  • Atul Deodhar

  • Pedro M. Machado

  • Victoria Navarro-Compán

  • Kay Geert Hermann

  • Mitsumasa Kishimoto

  • Eun Young Lee

  • Lianne S Gensler

  • Uta Kiltz

  • Marco Eigenmann

  • Patricia Pertel

  • Aimee Readie

  • Hanno B. Richards

  • Brian Porter

  • Juergen Braun

Medical Centers

  • Rheumazentrum Ruhrgebiet, Herne, Ruhr-Universität Bochum, Bochum, Nordrhein-Westfalen, Germany

  • Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

  • Charité – Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany

  • Department of Urology, Leiden Unviersity Medical Center, Leiden, Netherlands

  • Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR

  • Centre for Rheumatology & Department of Neuromuscular Diseases, UCL, London, United Kingdom

  • Department of Haematology,, University Hospital La Paz, Madrid, Spain

  • Department of Radiology, University Hospital Charité - Campus Mitte, Charitéplatz, Berlin, Germany

  • Department of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan

  • Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea., Seoul, Republic of Korea

  • Department of Medicine, Division of Gastroenterology, University of California, San Francisco, San Franciso, California, United States

  • Novartis AG, Basel, Switzerland

  • Novartis Pharma AG, Reinach, Switzerland

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Novartis Pharmaceuticals Corporation, Morrisville, NC

Locations

  • Brazil

  • Germany

  • Denmark

  • Netherlands

  • United States

  • United Kingdom

  • Spain

  • Japan

  • Republic of South Korea

  • Switzerland

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Musculoskeletal

Disease

  • Axial spondyloarthritis

  • Ankylosing spondylitis

  • Spondyloarthritis

Biomarkers

  • High sensitivity C-reactive protein

Drug/Treatment

  • Adalimumab biosimilar

  • secukinumab

  • Adalimumab

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Open Label

  • Superiority

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved